Hemogenyx Pharmaceuticals closed yesterday’s trading session down 1.85 percent, continuing the reversal of a strong bullish trend that had seen the company surge by over 10 percent in December.
What is Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals is a biopharmaceutical company that is focused on developing new therapies and treatments for blood diseases. The company is based in London and has US operating subsidiaries located in New York City. It is currently in the preclinical stage of development and is working on a range of product candidates and platform technologies that can be used to create novel products.
One of the main areas of focus for Hemogenyx Pharmaceuticals is the bone marrow/hematopoietic stem cell transplant market. The company is developing several products for this market, including CDX, a bi-specific antibody that targets relapsed/refractory acute myeloid leukemia; HEMO-CAR-T therapy, a chimeric antigen receptor T-cell therapy that is designed to identify and destroy human AML-derived cells in vitro and in vivo; and human postnatal hematopoietic endothelial cells, a stem cell therapy product for bone marrow/hematopoietic stem cell transplants.
The goal of Hemogenyx Pharmaceuticals is to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Bone marrow transplantation has been used for more than 50 years to save the lives of patients suffering from blood diseases, but the procedure is often only used as a last resort due to the risks of toxicity and death associated with it. The company’s technology has the potential to enable many more patients with conditions such as leukemia, lymphoma, and autoimmune diseases like multiple sclerosis, aplastic anemia, and systemic lupus erythematosus to benefit from bone marrow transplantation.
Should you invest in Hemogenyx Pharmaceuticals in 2023
There are many reasons why Hemogenyx Pharmaceuticals remains a top choice for most investors, including its continued work on developing therapies and treatments for blood disease. Recently, the company has completed he second and final Process Development run and the first Process Qualification run of the end-to-end process for the manufacture of HEMO-CAR-T cells, which are required for the submission of an Investigational New Drug application to the US Food and Drug Administration in order to authorize the commencement of Phase I clinical trials of HEMO-CAR-T.
Therefore, based on fundamental analysis of the company, it is looking highly likey that we might see continued performance of the company in the coming months. Therefore, going into 2023, Hemogenyx Pharmaceuticals is one of the companies that I expect to make a full recovery for this year’s 33 percent drop in value.
Daily Chart
